arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Monte Rosa Therapeutics, Inc.

GLUE
$11.88 ▼ -0.74 (-5.86%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Monte Rosa Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2B
Dividend Yield —
Revenue Growth -61.3% ↗
Op. Margin None
ROIC -10.1% ↘
FCF / Share $-0.48 ↘
Trailing P/E —
Price / Book 2.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.97M
↓ -61.3% —
Net Income Profit after all expenses
$-44.50M
— 0.0% —
Operating Margin Operating profit as % of sales
-258.3%
↓ -285.1% 6th
FCF / Share Free cash flow per share
$-0.48
↓ -22.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
7
Returns ↑
29
Cash Quality ↓
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 6 years · 27 quarters